Implementation of quality indicators from the S3 guideline palliative medicine for patients with non-curable cancer in clinical practice at palliative care units
- Conditions
- C00-C97Malignant neoplasms
- Registration Number
- DRKS00029965
- Lead Sponsor
- Medizinische Hochschule Hannover
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 893
AP1a: Responsible staff of the palliative care units in the commuting area of the CCC-N.
AP1b-1c: Data documented in clinical treatment routine of patients with cancer (ICD10 chapter malignant neoplasms: C00-C97) and a minimum age of 18 years with an inpatient stay of at least three nights at one of the participating palliative care units in the last 12 months prior to data collection.
AP2b-2c: Experts for inpatient palliative care, care providers in the cooperating clinics, for example clinical specialists (medical and nursing managers at palliative care units), stakeholders at the meso and macro level of the health care system (e.g. staff from the hospice and palliative care association, from the medical guideline programm oncology and from the coordination centre for palliative medicine of the CCC-N).
AP1a, 2b-2c: No adequate knowledge of the German language.
AP1b-1c: Death, transfer or discharge before the end of the third night or/and lack of consent for the scientific use of patient data.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) A comprehensive picture of the practical implementation of the quality indicators of the S3 guideline palliative medicine in clinical practice on palliative care units in the commuting area of the CCC-N<br><br>2) Recommendations for adapting and optimising the implementation of guideline contents on palliative care units
- Secondary Outcome Measures
Name Time Method Arm 1 and 2: In particular, it will be investigated which quality indicators are implemented in clinical practice and how they are documented as well as which facilitating and detaining factors have an influence on the implementation of the S3 guideline palliative medicine.